Zepp Health (NYSE:ZEPP) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Zepp Health (NYSE:ZEPP) from a hold rating to a sell rating in a research report sent to investors on Tuesday,Wall Street Zen reports.

Separately, Fundamental Research set a $53.01 target price on Zepp Health and gave the company a “buy” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $53.01.

Zepp Health Price Performance

NYSE ZEPP opened at $4.90 on Tuesday. The firm’s fifty day simple moving average is $5.07 and its two-hundred day simple moving average is $9.90. The firm has a market capitalization of $71.93 million, a P/E ratio of -1.78 and a beta of 1.87. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.30. Zepp Health has a 12-month low of $3.85 and a 12-month high of $61.85.

Insider Buying and Selling at Zepp Health

In other news, CFO Cheng Deng sold 9,836 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $4.61, for a total value of $45,343.96. Following the completion of the transaction, the chief financial officer owned 114,539 shares of the company’s stock, valued at $528,024.79. The trade was a 7.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 36.00% of the company’s stock.

Institutional Trading of Zepp Health

Several hedge funds and other institutional investors have recently bought and sold shares of ZEPP. AXQ Capital LP acquired a new position in Zepp Health in the second quarter valued at approximately $85,000. Millennium Management LLC increased its holdings in shares of Zepp Health by 49.1% during the 4th quarter. Millennium Management LLC now owns 366,826 shares of the company’s stock valued at $9,882,000 after purchasing an additional 120,750 shares in the last quarter. Balyasny Asset Management L.P. lifted its stake in shares of Zepp Health by 46.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 202,775 shares of the company’s stock valued at $5,463,000 after purchasing an additional 64,692 shares during the period. FIL Ltd acquired a new position in shares of Zepp Health in the 4th quarter valued at $16,858,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Zepp Health by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 295,967 shares of the company’s stock worth $7,974,000 after buying an additional 44,619 shares in the last quarter. 52.61% of the stock is owned by institutional investors and hedge funds.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.